Featured Stories
Accelerated Approval: Nippon Shinyaku’s Viltepso Fails DMD Confirmatory Trial, Raising Questions
The Duchenne muscular dystrophy treatment missed its primary endpoint of time to stand from supine in the RACER53 study, raising more questions about using dystrophin changes to support accelerated approval and the ability of functional endpoints to detect clinical change.
To Join Or Not To Join: The Challenges Of A Joint FDA-Sponsor Adcomm Briefing Document
3D Communications’ Nathan Gede says challenges related to submission timing, length and review format explain why sponsors may be reluctant to agree to a “point-counterpoint” style advisory committee briefing document, despite the Oncology Center of Excellence’s move in that direction.
EU Crunch Time For Myriad Drugs Marks A Busy May Meeting For CHMP
The latest meeting of the European Medicines Agency’s human medicines committee, the CHMP, is taking place this week. Decisions are expected for 13 drug marketing applications, there will be a number of oral explanation meetings, and activity is expected relating to a drug at the center of a case involving the European Commission’s rejection of an EMA recommendation.
Clinical Trial Reform
‘Antiquated’ Regulations Slowing Adoption of Innovative Clinical Trial Approaches
The current regulations were written when clinical trials involved far fewer entities, and a certain amount of ‘contortion’ is necessary when sponsors are trying to introduce decentralized, community-based and other modern elements, the FDA’s Kevin Bugin says in an interview with the Pink Sheet.
US FDA Looking To Modernize Clinical Trial Regulations To Spur ‘Evolution’ In Research
US FDA Focuses On Labs, Concomitant Medication To Avert Needless Clinical Trial Exclusions
Cancer Trials: FDA Wants Lower Performance Status Eligibility But Primary Analysis Exclusion OK
France Consults On Best Practice Guidelines For Decentralized Trials
Latest News
Pink Sheet Podcast
Keep up with latest biopharma regulatory and policy developments with Pink Sheet podcasts.
More PodcastsPerformance Trackers
PTC’s Upstaza Takes Gene Therapy Straight To Brain (And US FDA); Translarna To Return Mid-Year
In a year full of regulatory milestones for the firm, PTC Therapeutics hopes to set some approval precedents – and basically hopes its candidates have an easier time of it than they have had before.
Global Pharma Guidance Tracker – April 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
US FDA Performance Tracker
European Performance Tracker
Multimedia
US FDA’s Novel Approvals Peak Near Year-End, Analysis Of Last Decade Suggests
The Center for Drug Evaluation and Research’s novel approvals concentrated in August, November, and December, while January and June were the slowest months, according to a Pink Sheet analysis of 2014-2023 data.
Weight Loss, Diabetes Treatments Focus Of FTC's Second Round Of Patent Listing Challenges
The Pink Sheet takes a deep dive into the Federal Trade Commission's second wave of challenges to patents it asserts are improperly listed in the FDA's Orange Book, including patents covering Novo Nordisk's self-injection pens for Saxenda (liraglutide) and Ozempic (semaglutide).
As Biosecure Bill Moves Forward, Clock Ticking For Industry To Move Away From Chinese CDMOs
Pink Sheet infographic details the timeframes and potential extensions under the House version of the bill, which just cleared committee.
US FDA Transparency Win: Sponsors Know More Product-Specific Guidances Coming, Requests Fall
After creating a list of anticipated product-specific guidances to be published for generic sponsors and increasing PSG production, public requests for the agency to write a PSG declined.
Regional Comparisons
Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?
EMA charges participants to receive scientific advice through the fledgling program, unlike the US FDA, which may not fit the budgets of some complex generic sponsors. At the same time, sponsors also may simply not be aware the program exists yet.
For Generics, EU Reference Product Is Non-Negotiable – Even In Pilot On Parallel Advice
Acknowledging that it may be a barrier to some extent, EMA’s senior scientific specialist of clinical pharmacology Kevin Blake notes that EU reference medicinal products are a legal requirement for bioequivalence studies and cannot be circumvented.
How The EU & UK’s Contrasting Approaches To AI Regulation Could Impact Pharma
While EU preparations are underway to introduce strict legal requirements for all AI systems, the UK has doubled down on its flexible, non-regulatory framework. In this second of a two-part article, a lawyer explains the pros and cons of each for pharma and medtech firms.
For Psychedelics, US FDA Is Open To Creative Thinking But Firm On Approval Standards
Flexible thinking and rigorous standards will both be needed to develop psychedelics as drug therapies in order to surmount the many complicating factors, from unique ‘set and setting’ aspects to functional unblinding, speakers at Reagan-Udall Foundation meeting agree.
Recent Stories
Pandemic Treaty Talks Flounder But WHO Still Holds Out Hope For Eventual Agreement
At this week’s World Health Assembly, a working group will be set up to discuss the next steps for talks on a global pandemic treaty and try to reach a final agreement on amendments to the International Health Regulations.
How Pharma Can Use England’s Genomics Data To Improve Regulatory Filings & Trial Design
A real-world data research partnership involving Genomics England is helping pharma companies to continuously draw “more insights” from genomic information to improve their regulatory submissions and optimize trials.
Platform Tech Designation: US FDA Emphasizes “Significant Efficiencies” Criteria In New Guidance
New draft guidance defines the necessary components of a platform technology designation request, including that sponsors demonstrate how it will save the FDA review time.
‘Pivotal’ Regulation On EU Joint Clinical Assessments Extends Dossier Deadlines
Despite changes, industry remains concerned over the EU implementing regulation that sets out procedures for joint clinical assessments.
Joint Clinical Assessments Of ATMPs Add To Ethical Concerns Over Need For Randomized Trials
Advances in cell and gene therapy, together with the forthcoming EU joint clinical assessments, have raised questions about the ethics of having to use randomized controlled trials to test new advanced therapies.
Citeline Japan Awards 2024 - Enter Now!
The 15 July entry deadline for the Citeline Japan Awards 2024 in Tokyo is fast approaching, so here's a reminder to take a look at the categories and criteria and be sure you get those submissions in by this date. Sponsorship opportunities and tables are also available.
International Health Regulation Changes Focus On Equitable Access And Production Capacity
The final version of amendments to the IHR is due to be discussed at this week’s World Health Assembly, alongside the way forward for the proposed global pandemic treaty.
Global CRO Body Seeks US-Based Trial Sites With Novel Ideas For Improving Diversity
The Association of Clinical Research Organizations is offering to help clinical trials sites that want to make diversity and inclusion improvements, and generate learnings for the broader industry.
Lessons Learned From COVID-19 That Are Key To Future Global Pandemic Response
Panelists at a webinar discussed what went awry in the global response to the COVID-19 pandemic and the lessons to be learned in future in areas such as procurement, equitable access and regulatory processes.
Novo’s Insulin Icodec Hypoglycemia Risk Outweighs Limited Benefit In Type 1 Diabetes–FDA Panel
The Endocrinologic and Metabolic Drugs Advisory Committee majority says new studies should validate the proposed risk mitigation measures before approval for T1D.
US FDA Drug Center Tries New Approach To Old Consistency Problems
Drug developers should not expect the US FDA's new Quantitative Medicine Center of Excellence to dramatically impact the agency's long-standing problem of ensuring more consistent use of innovative regulatory approaches in application reviews.
US FDA’s Novel Approvals Peak Near Year-End, Analysis Of Last Decade Suggests
The Center for Drug Evaluation and Research’s novel approvals concentrated in August, November, and December, while January and June were the slowest months, according to a Pink Sheet analysis of 2014-2023 data.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.